Tyrosine kinase inhibitors (TKIs) inhibit the initiation of the BCR-ABL1 pathway and are effective, frontline therapies for chronic phase (CP) CML (CML-CP) [3]. Here, ABL1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.